Scarpellini E., Luigiano C., Svegliati-Baroni G., Dumitrascu D., Larussa T., Santori V., et al. Liver Cirrhosis Complications M anagement at the Emergency Department. Rev Recent. Clin Trials. 2020;15(4):331-338. DOI: 10.2174/1574887115666200603160816.
DOI: 10.2174/1574887115666200603160816

EASL Clinical Practice Guidelines for the management of patients with decompensated cirrhosis. J Hepatol. 2018;69(2):406-460. DOI: 10.1016/j.jhep.2018.03.024.
DOI: 10.1016/j.jhep.2018.03.024

Angeli P., Garcia-Tsao G., Nadim M.K., Parikh C.R. News in pathophysiology, definition and classification of hepatorenal syndrome: A step beyond the International Club of Ascites (ICA) consensus document. J Hepatol. 2019;71(4):811-822. DOI: 10.1016/j.jhep.2019.07.002.
DOI: 10.1016/j.jhep.2019.07.002

Simonetto D. A., Gines P., Kamath P.S. Hepatorenal syndrome: pathophysiology, diagnosis, and management. BMJ. 2020;370:m2687. DOI: 10.1136/bmj.m2687.
DOI: 10.1136/bmj.m2687

Alessandria C., Ozdogan O., Guevara M., RestucciaT., Jimenez W., Arroyo V., et al. MELD score and clinical type predict prognosis in hepatorenal syndrome: Relevance to liver transplantation. Hepatology. 2005;41:1282-1289. DOI: 10.1002/hep.20687..
DOI: 10.1002/hep.20687

Bucsics T., Krones E. Renal dysfunction in cirrhosis: acute kidney injury and the hepatorenal syndrome. Gastroenterol Rep (Oxf). 2017;5(2):127-137. DOI: 10.1093/gastro/gox009.
DOI: 10.1093/gastro/gox009

Tujios S.R., Hynan L.S., Vazquez M.A., Larson A.M., Seremba E., Sanders C.M., et al. Acute Liver Failure Study Group. Risk factors and outcomes of acute kidney injury in patients with acute liver failure. Clin Gastroenterol Hepatol. 2015;13:352-359. DOI: 10.1016/j.cgh.2014.07.011..
DOI: 10.1016/j.cgh.2014.07.011

Mindikoglu A. L. New Developments in hepatorenal syndrome. Clin Gastroenterol. Hepatol. 2018; 16(2): 162-177. DOI: 10.1016/j.cgh.2017.05.041.
DOI: 10.1016/j.cgh.2017.05.041

Trawa^ J.M., Paradis V., Rautou P.E., Francoz C., Escolano S., Sal^e M., et al. The spectrum of renal lesions in patients with cirrhosis: a clinicopathological study. Liver Int. 2010;30:725-732. DOI: 10.1111/j.1478-3231.2009.02182.x.
DOI: 10.1111/j.1478-3231.2009.02182.x

Sherman DS, Fish DN, Teitelbaum I. Assessing renal function in cirrhotic patients: problems and pitfalls. Am J Kidney Dis. 2003;41:269-278. DOI: 10.1053/ajkd.2003.50035.
DOI: 10.1053/ajkd.2003.50035

Francoz C, Glotz D, Moreau R, Durand F. The evaluation of renal function and disease in patients with cirrhosis. J Hepatol. 2010;52:605-613. DOI: 10.1016/j.jhep.2009.11.025.
DOI: 10.1016/j.jhep.2009.11.025

Cocchetto DM, Tschanz C, Bjornsson TD. Decreased rate of creatinine production in patients with hepatic disease: implications for estimation of creatinine clearance. Ther Drug Monit. 1983;5:161-168. DOI: 10.1097/00007691-19830600000002.
DOI: 10.1097/00007691-19830600000002

Francoz C., Prie D., Abdelrazek W. Moreau R., Mandot A., Belghiti J., et al. Inaccuracies of creatinine and creatinine-based equations in candidates for liver transplantation with low creatinine: impact on the model for end-stage liver disease score. Liver Transplant. 2010;16:1169-77. DOI: 10.1002/lt.22128.
DOI: 10.1002/lt.22128

Nadim M.K., Kellum J.A., Davenport A., Wong F., Davis C., Pannu N., et al. Hepatorenal syndrome: the 8th international consensus conference of the Acute Dialysis Quality Initiative (ADQI) Group. Crit Care. 2012;16:R23. DOI: 10.1186/cc11188.
DOI: 10.1186/cc11188

Stevens L.A., Coresh J., Greene T., Levey A.S. Assessing kidney function--measured and estimated glomerular filtration rate. N Engl J Med. 2006; 354:2473-2483. DOI: 10.1056/NEJMra054415.
DOI: 10.1056/NEJMra054415

Cholongitas E, Shusang V, Marelli L., Nair D., Thomas M., Patch D., et al. Review article: renal function assessment in cirrhosis— difficulties and alternative measurements. Aliment Pharmacol Ther. 2007;26:969-978. DOI: 10.1111/j.1365-2036.2007.03443.x.
DOI: 10.1111/j.1365-2036.2007.03443.x

Krones E., Fickert P., Zitta S. Neunherz S.,Artinger K.,Reibnegger G. et al. The chronic kidney disease epidemiology collaboration equation combining creatinine and cystatin C accurately assesses renal function in patients with cirrhosis. BMC Nephrol. 2015;16:1-10. DOI: 10.1186/s12882-015-0188-0.
DOI: 10.1186/s12882-015-0188-0

Mindikoglu A.L., Dowling T.C., Weir M.R., Seliger S.L., Christenson R.H., Magder L.S. Performance of chronic kidney disease epidemiology collaboration creatinine-cystatin C equation for estimating kidney function in cirrhosis. Hepatology. 2014;59:1532-1542. DOI: 10.1002/hep.26556.
DOI: 10.1002/hep.26556

Arroyo V. A new method for therapeutic paracentesis: The automated low flow pump system. Comments in the context of the history of paracentesis. J Hepathology. 2013;58(5):850-852. DOI: 10.1016/j.jhep.2013.01.037.
DOI: 10.1016/j.jhep.2013.01.037

Stevens L.A., Schmid C.H., Greene T. Li L., Beck G.J., Joffe M.M., et al. Factors other than glomerular filtration rate affect serum cystatin C levels. Kidney Int. 2009;75:652-60. DOI: 10.1038/ki.2008.638.
DOI: 10.1038/ki.2008.638

Al-Hazmi SF., Gad H.G.M., Alamoudi A.A., Eldakhakhny B.M., Binmahfooz S.K., Alhozali A.M. Evaluation of early biomarkers of renal dysfunction in diabetic patients. Saudi Med J. 2020;41(7):690-697. DOI: 10.15537/smj.2020.7.25168..
DOI: 10.15537/smj.2020.7.25168

Rao X., Wan M., Qiu C., Jiang C. Role of cystatin C in renal damage and the optimum cut-off point of renal damage among patients with type 2 diabetes mellitus. Experimental and therapeutic medicine. 2014; 8(3): 887-892. DOI: 10.3892/etm.2014.1815.
DOI: 10.3892/etm.2014.1815

Singal Russ K.B., Stevens T.M., Singal A.K. Acute Kidney Injury in Patients with Cirrhosis. J Clin Transl Hepatol. 2015;3(3):195-04. DOI: 10.14218/JCTH.2015.00015.
DOI: 10.14218/JCTH.2015.00015

Martm-LlafuM, Guevara M, Torre A, Fagundes C, Restuccia T, Gilabert R, et al. Prognostic importance of the cause of renal failure in patients with cirrhosis. Gastroenterology. 2011;140(2):488. DOI: 10.1053/j.gastro.2010.07.043.
DOI: 10.1053/j.gastro.2010.07.043

Mandorfer M., Bota S., Schwabl P., Bucsics T., Pfisterer N., Kruzik M., et al. Nonselective в blockers increase risk for hepatorenal syndrome and death in patients with cirrhosis and spontaneous bacterial peritonitis. Gastroenterology. 2014;146:1680-90.el. DOI: 10.1053/j.gastro.2014.03.005.
DOI: 10.1053/j.gastro.2014.03.005

Boyer T.D., Sanyal A.J., Wong F., Frederick R.T., Lake J.R., O'Leary J.G., et al. Terlipressin plus albumin is more effective than albumin alone in improving renal function in patients with cirrhosis and hepatorenal syndrome type 1. Gastroenterology. 2016;150:1579-1589. DOI: 10.1053/j.gastro.2016.02.026.
DOI: 10.1053/j.gastro.2016.02.026

Cavallin M., Kamath P.S., Merli M., Fasolato S., Toniutto P., Salerno F., et al. Terlipressin plus albumin vs. midodrine and octreotide plus albumin in the treatment of hepatorenal syndrome: A randomized trial. Hepatology. 2015;62:567-574. DOI: 10.1002/hep.27709.
DOI: 10.1002/hep.27709

Cavallin M., Piano S., Romano A., Fasolato S., Frigo A.C., Benetti G., et al. Terlipressin given by continuous intravenous infusion vs. intravenous boluses in the treatment of hepatorenal syndrome: A randomized controlled study. Hepatology. 2016;63:983-992. DOI: 10.1002/hep.28396.
DOI: 10.1002/hep.28396

Piano S., Schmidt H.H., Ariza X., Amoros A., Romano A., Sola E., et al. Impact of Acute-on-Chronic Liver Failure on response to treatment with terlipressin and albumin in patients with type 1 hepatorenal syndrome. Digestive and Liver Disease. 2017;49(1): e54. DOI: 10.1016/j.dld.2017.01.108.
DOI: 10.1016/j.dld.2017.01.108

Глумчер Ф.С. Возможности применения альбумина в терапии критических состояний: современное состояние проблемы. Медицина неотложных состояний. 2014;2(57):65-73.

Смирнов А.В., Румянцев А.Ш.* от имени рабочей группы. Острое повреждение почек. Часть I. Нефрология. 2020;24(1):67- 95. DOI: 10.36485/1561-6274-2020-24-1-67-95.
DOI: 10.36485/1561-6274-2020-24-1-67-95

Angeli P., Gines P., Wong F., Bernardi M., Boyer T.D., Gerbes A., et al. Diagnosis and management of acute kidney injury in patients with cirrhosis: revised consensus recommendations of the International Club of Ascites. J Hepatol. 2015;62:968-974. DOI: 10.1016/j.jhep.2014.12.029.
DOI: 10.1016/j.jhep.2014.12.029

Nadim M.K., Durand F., Kellum J.A. Levitsky J., O'Leary J.G., Karvellas C.J., et al. Management of the critically ill patient with cirrhosis: A multidisciplinary perspective. J Hepatol. 2016; 64:717-735. DOI: 10.1016/j.jhep.2015.10.019.
DOI: 10.1016/j.jhep.2015.10.019

O'Leary J.G., Levitsky J., Wong F., Nadim M. K., Charlton M., Kim W. R. Protecting the kidney in liver transplant candidates Practice Based Recommendations from the American Society of Transplantation Liver and Intestine Community of Practice. Am J Transplant. 2016;16(9):2516-2531. DOI: 10.1111/ajt.13790.
DOI: 10.1111/ajt.13790

35. Mindikoglu A.L., Dowling T.C., Wong-You-Cheong J.J., Christenson R.H., Magder L. S., Hutson W. R., et al. A pilot study to evaluate renal hemodynamics in cirrhosis by simultaneous glomerular filtration rate, renal plasma flow, renal resistive indices and biomarkers measurements. Am J Nephrol. 2014; 39:543-552. DOI: 10.1159/000363584.
DOI: 10.1159/000363584

Rivolta R., Maggi A., Cazzaniga M., Castagnone D.,Panzeri A., Solenghi D., et al. Reduction of renal cortical blood flow assessed by Doppler in cirrhotic patients with refractory ascites. Hepatology. 1998; 28:1235-1240. DOI: 10.1002/hep.510280510.
DOI: 10.1002/hep.510280510

Mindikoglu A.L., Weir M.R. Current concepts in the diagnosis and classification of renal dysfunction in cirrhosis. Am J Nephrol. 2013; 38:345-354. DOI: 10.1159/000355540.
DOI: 10.1159/000355540

Fagundes C., Pepin M.N., Guevara M., Barreto R., Casals G., Sola E., et al. Urinary neutrophil gelatinase-associated lipocalin as biomarker in the differential diagnosis of impairment of kidney function in cirrhosis. J Hepatol. 2012; 57:267-273. DOI: 10.1016/j.jhep.2012.03.015.
DOI: 10.1016/j.jhep.2012.03.015

Belcher J.M., Sanyal A.J., Peixoto A.J., Perazella M.A., Lim J., Thiessen-Philbrook H., et al. Kidney biomarkers and differential diagnosis of patients with cirrhosis and acute kidney injury. Hepatology. 2014; 60:622-632. DOI: 10.1002/hep.26980.
DOI: 10.1002/hep.26980

Лихота О.С., Цикуниб А.Д. Особенности метаболизма и маркеры биохимических нарушений в печени при гепатитах. Наука: комплексные проблемы. - 2017;1(9):4-11.

41. Саварина В.А., Мицура В.М., Скуратов А.Г., Мартемьянова Л.А. Проблемы диагностики гепаторенального синдрома в практике клинициста и патологоанатома. Проблемы Здоровья и Экологии. 2020;65(3):49-55.

Сливка Н.А., Вирстюк Н.Г., Давыденко И.С., Мартынюк Г.А., Бевз Т.И., Гайдуков В.А. Гистологические изменения почек при гепаторенальном синдроме на фоне алкогольного цирроза печени. Клиническая и экспериментальная патология. 2018;4(66):71-75. DOI: 10.24061/1727-4338.XVII.4.66.2018.191.
DOI: 10.24061/1727-4338.XVII.4.66.2018.191

Вирстюк Н.Г., Сливка Н.А. Диагностическая ценность допплерографического исследования при гепаторенальном синдроме. Гастроэнтерология. 2017;1(51):8-15. DOI: 10.22141/2308-2097.51.1.2017.97866.
DOI: 10.22141/2308-2097.51.1.2017.97866